NASDAQ$RYTM
Rhythm Pharmaceuticals Inc · Q4 2020 earnings
Q4 2020 earnings · · Investor relations
Briefing
Reported financial results for the fourth quarter and full year ended December 31, 2020, and provided a business update.
Rhythm Pharmaceuticals reported its Q4 and full-year 2020 financial results, highlighting the FDA approval of IMCIVREE™ and positive topline data from a Phase 3 trial. The company is well-funded to advance setmelanotide's development and commercialization.
- Received FDA approval of IMCIVREE™ (setmelanotide) for chronic weight management in patients with obesity due to POMC, PCSK1 or LEPR deficiency.
- Announced positive topline data from Phase 3 pivotal trial evaluating setmelanotide in Bardet-Biedl and Alström syndromes.
- Announced data from five cohorts in Phase 2 Basket Study demonstrating proof-of-concept in HET POMC, PCSK1 or LEPR deficiencies, and obesity due to SRC1 and SH2B1 deficiencies.
- Strengthened financial position with net proceeds of $98.5M from sale of Rare Pediatric Disease PRV and $161.6M from public offering, extending cash runway through at least the second half of 2023.
Headline financials
Revenue & EPS history
Rhythm Pharmaceuticals · Revenue · Quarterly
$60.1M
Forward guidance
Rhythm expects to achieve key commercial, regulatory, and clinical milestones in 2021, including making IMCIVREE commercially available in the United States and Europe, completing regulatory submissions for setmelanotide in BBS, and initiating new clinical trials.
Tailwinds
- Make IMCIVREE commercially available in the United States for obesity due to POMC, PCSK1 and LEPR deficiencies in the first quarter of 2021.
- Obtain regulatory approval from the European Commission and make IMCIVREE commercially available in Europe in POMC, PCSK1 and LEPR deficiency obesities in the second half of 2021.
- Complete regulatory submissions to both the FDA and the EMA seeking marketing authorization for setmelanotide for the treatment of obesity in patient with BBS in the second half of 2021.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2020
+3.1%
Avg return
Earnings day
+2.4%
Avg return
5 days after
+5.4%
Avg return
30 days after
53%
18 / 34 earnings
Positive
+40.8%
Q2 2022
Best reaction
-15.7%
Q2 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +8.2% | +10.3% | +2.5% | |
| Q4 2025 | -0.9% | -9.7% | -23.5% | |
| Q3 2025 | -7.7% | -11.8% | -7.1% | |
| Q1 2025 | +2.9% | -6.0% | +8.6% | |
| Q4 2024 | +4.5% | +2.7% | +7.4% | |
| Q3 2024 | +18.2% | +27.1% | +9.1% | |
| Q2 2024 | -1.1% | +2.8% | +9.6% | |
| Q1 2024 | -11.3% | -10.8% | -9.6% | |
| Q4 2023 | -7.5% | -5.7% | -16.9% | |
| Q3 2023 | +1.2% | +5.1% | +40.3% | |
| Q2 2023 | +36.3% | +37.0% | +45.8% | |
| Q1 2023 | -8.4% | -17.4% | -15.0% | |
| Q4 2022 | +0.1% | -9.8% | -26.6% | |
| Q3 2022 | -2.5% | +15.5% | +15.7% | |
| Q2 2022 | +40.8% | +62.6% | +103.5% | |
| Q1 2022 | -12.5% | -32.1% | -46.0% | |
| Q4 2021 | +21.3% | +21.7% | +51.2% | |
| Q3 2021 | +14.4% | +14.9% | -24.0% | |
| Q2 2021 | -15.7% | -17.5% | -22.1% | |
| Q1 2021 | -0.1% | +2.6% | -10.5% | |
| Q4 2020 | +3.2% | +0.2% | -17.9% | |
| Q3 2020 | +8.8% | +7.9% | +51.2% | |
| Q2 2020 | -2.4% | -1.8% | +55.2% | |
| Q1 2020 | +7.1% | +8.7% | +10.9% | |
| Q4 2019 | +3.0% | -5.4% | -22.1% | |
| Q3 2019 | +0.6% | -1.3% | +5.3% | |
| Q2 2019 | -4.7% | -2.9% | +11.7% | |
| Q1 2019 | -0.7% | -1.0% | -2.4% | |
| Q4 2018 | +5.8% | +8.2% | +1.6% | |
| Q3 2018 | -12.3% | -15.3% | -13.1% | |
| Q2 2018 | -1.3% | -2.8% | -5.9% | |
| Q1 2018 | +17.8% | +21.2% | +29.9% | |
| Q4 2017 | +6.9% | -16.3% | -24.0% | |
| Q3 2017 | -5.7% | +1.3% | +10.1% | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — | |
| Q4 2016 | — | — | — | |
| Q3 2016 | — | — | — | |
| Q2 2016 | — | — | — | |
| Q1 2016 | — | — | — | |
| Q4 2015 | — | — | — | |
| Q3 2015 | — | — | — | |
| Q2 2015 | — | — | — | |
| Q1 2015 | — | — | — | |
| Q4 2014 | — | — | — | |
| Q3 2014 | — | — | — | |
| Q2 2014 | — | — | — | |
| Q1 2014 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro